Public Awareness Gap Persists as Cardiovascular-Kidney-Metabolic Syndrome Affects Nearly Ninety Percent of US Adults
The American landscape of chronic disease is undergoing a fundamental shift in definition, yet public understanding remains significantly behind the curve of clinical reality. According to a comprehensive new survey released by the American Heart Association, a vast majority of United States adults remain unfamiliar with Cardiovascular-Kidney-Metabolic (CKM) syndrome, a condition that medical experts now estimate affects nearly 90% of the adult population. Despite this lack of name recognition, the survey reveals a critical opportunity for public health intervention, as most respondents expressed a strong desire to understand the interconnected nature of their heart, kidney, and metabolic health.
CKM syndrome is a relatively recent clinical designation that recognizes the deep, systemic links between heart disease, kidney disease, Type 2 diabetes, and obesity. For decades, these conditions were largely treated as separate entities by different specialists—cardiologists, nephrologists, and endocrinologists. However, the American Heart Association (AHA) has moved to codify CKM syndrome to reflect the scientific reality that these organs and systems function in a delicate, symbiotic balance. When one system falters, it triggers a domino effect that accelerates decline in the others.
The Anatomy of a Modern Health Crisis
The prevalence of CKM syndrome is driven by a cluster of common risk factors that have reached epidemic proportions in the United States. These include hypertension (high blood pressure), dyslipidemia (abnormal cholesterol levels), hyperglycemia (high blood sugar), excess adiposity (obesity), and chronic kidney disease (CKD). The AHA reports that nearly nine out of ten U.S. adults possess at least one of these risk factors.
The danger of CKM syndrome lies in its synergistic effect. While a single condition like high blood pressure is a significant health concern, its combination with reduced kidney function and insulin resistance creates a compounded risk profile. When these issues occur simultaneously, the statistical likelihood of experiencing a major adverse cardiac event—such as a heart attack, stroke, or heart failure—rises exponentially compared to the risk posed by any single condition in isolation.
Dr. Eduardo Sanchez, the American Heart Association’s chief medical officer for prevention, emphasized that the interconnectedness of these systems is both a challenge and an opportunity. "We want people to know that it’s really common to have heart, kidney and metabolic risk factors at the same time," Sanchez stated. He noted that while the terminology is new to the public, the underlying concept resonates once explained. "It is reassuring that once the CKM connection was defined, nearly three-quarters of those responding understood that it was important and wanted to learn more."
A Chronology of the CKM Framework
The formal recognition of CKM syndrome is the result of years of evolving clinical observation. The timeline of this medical paradigm shift highlights the urgency of the AHA’s current educational push:
- Pre-2023: Chronic diseases were largely managed through "siloed" care. Patients with diabetes saw endocrinologists, while those with heart failure saw cardiologists, often with little communication between the two regarding the shared metabolic roots of their conditions.
- October 2023: The American Heart Association officially defined Cardiovascular-Kidney-Metabolic syndrome in a presidential advisory published in the journal Circulation. This document established the staging system for the syndrome, ranging from Stage 0 (no risk factors) to Stage 4 (symptomatic cardiovascular disease with kidney and metabolic components).
- August 2025: The Harris Poll, on behalf of the AHA, conducted a massive survey of 4,007 U.S. adults to gauge public awareness of the new designation. This survey provided the data showing the massive gap between disease prevalence and public knowledge.
- Early 2026: The American Heart Association is scheduled to release the first-ever comprehensive clinical guidelines specifically focused on the management of CKM syndrome. These guidelines will provide healthcare providers with a unified roadmap for treating the syndrome as a single, multi-system disorder.
Deep Dive into the Harris Poll Findings
The August 2025 survey, conducted by The Harris Poll, offers a sobering look at the state of public health literacy. The study included a diverse sample of approximately 4,000 participants, weighted to reflect the U.S. census across demographics such as age, gender, race, and socioeconomic status.
The results highlighted several major gaps in understanding. Most notably, while many Americans are aware they have "high blood pressure" or "high sugar," very few understand how these conditions damage the kidneys or how kidney dysfunction, in turn, causes the heart to thicken and eventually fail. The survey revealed that the term "CKM syndrome" was virtually unknown to the general public prior to the survey interaction.
However, the data also pointed to a significant "teachable moment." Approximately 75% of respondents indicated that once they were told about the connection between the heart, kidneys, and metabolism, they viewed it as a high priority for their personal health management. This suggests that the barrier to better health outcomes is not a lack of interest, but a lack of accessible, integrated medical communication.
The Stages of CKM Syndrome: A Preventive Roadmap
To help the public and clinicians navigate this complex syndrome, the AHA has categorized CKM into five distinct stages. This staging allows for earlier intervention and, in many cases, the reversal of the condition before permanent organ damage occurs.
- Stage 0: No CKM risk factors. The goal is primary prevention through lifestyle maintenance.
- Stage 1: Excess body fat or unhealthy fat distribution (such as abdominal obesity) or impaired glucose tolerance. At this stage, the risk of heart disease and kidney disease begins to climb.
- Stage 2: Inclusion of metabolic risk factors (Type 2 diabetes, high blood pressure, high triglycerides) or moderate-to-high-risk chronic kidney disease.
- Stage 3: Early-stage cardiovascular disease that has not yet produced symptoms but can be detected through screening, particularly in people with high-risk kidney disease or metabolic issues.
- Stage 4: Symptomatic cardiovascular disease in people with CKM risk factors. This stage includes those who have already suffered a heart attack or stroke or who have developed heart failure.
The AHA emphasizes that CKM syndrome is not a one-way street. Through aggressive changes in eating habits, consistent physical activity, and modern medical treatments—including newer classes of medications like SGLT2 inhibitors and GLP-1 receptor agonists—patients can actually move backward through the stages, improving their health and extending their life expectancy.
Implications for Healthcare and Collaborative Care
The rise of CKM syndrome as a recognized clinical entity necessitates a transformation in how healthcare is delivered in the United States. For decades, the American medical system has been criticized for its fragmented nature. A patient with CKM syndrome might be prescribed medications by three different doctors, sometimes resulting in drug interactions or redundant testing.
"The heart, kidney and metabolic systems are connected and, as such, should be treated in a coordinated way," Sanchez said. "These results reveal the need to emphasize those connections and help patients understand the importance of collaborative care."
This collaborative approach, often referred to as interdisciplinary care, involves a "team-based" model where primary care physicians work in lockstep with specialists. The AHA’s CKM Health Initiative is currently working with healthcare teams nationwide to provide educational tools and resources to facilitate this shift. The goal is to move toward a "whole-patient" view, where a single treatment plan addresses the metabolic drivers of both heart and kidney decline.
The Economic and Social Impact
The implications of failing to address CKM syndrome are not only medical but also economic. Chronic diseases are the leading drivers of the $4.5 trillion in annual healthcare costs in the United States. Heart disease and diabetes alone account for hundreds of billions of dollars in direct medical expenses and lost productivity.
By identifying CKM syndrome early—at Stage 1 or 2—the healthcare system could potentially save billions of dollars by preventing the progression to Stage 4, which often requires expensive interventions like dialysis, heart surgery, or long-term hospitalizations. Furthermore, because CKM risk factors are disproportionately prevalent in underserved communities, addressing the syndrome through a unified framework is seen by many experts as a vital step toward achieving health equity.
Taking Action: The Path to 2026
As the medical community prepares for the 2026 clinical guidelines, the American Heart Association is focusing its efforts on public education. A new online resource hub and educational videos are being deployed to simplify the complex science of CKM health. These resources focus on "2 truths": that the systems are connected, and that taking care of one helps the others.
The CKM Health Initiative is supported by a coalition of major industry players, including founding sponsors Novo Nordisk and Boehringer Ingelheim, highlighting the private sector’s recognition of the syndrome’s importance.
For the average American, the message from the AHA is clear: overall health is a "full circle." Regular monitoring of blood pressure, cholesterol, weight, blood sugar, and kidney function is no longer just a series of checkboxes—it is a comprehensive strategy for maintaining the delicate balance of the body’s most vital systems. As public awareness catches up to clinical science, the hope is that the 90% of adults currently at risk can begin to reverse the trend, one metabolic marker at a time.
Related posts:
